In this issue:
Nivolumab + ipilimumab with chemotherapy as first-line treatment for metastatic NSCLC
Durvalumab after sequential chemoradiotherapy in unresectable stage III NSCLC
Thoracic cancer exercise services in Australia
Sotorasib plus carboplatin-pemetrexed for advanced nonsquamous KRAS G12C NSCLC
Comorbidities: impact on mortality benefits of lung cancer screening
Amivantamab + lazertinib for EGFR-mutated NSCLC after progression
Repeated pulmonary resection for second primary NSCLC
Impact of immune-related adverse event severity in ICI-treated advanced NSCLC
Treatments after failed consolidation durvalumab in stage III unresectable NSCLC
Sacituzumab govitecan as second-line therapy for extensive-stage SCLC
Please login below to download this issue (PDF)